Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)

Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)

The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030, increasing at a CAGR of 29.41%, for the period of 2021-2030. The factors such as growth of pharmaceutical industry, increase in ageing population, upsurge in healthcare expenditure, urbanization leading to better monitoring and screening procedures and increase in liver cancer and cirrhosis deaths due to HBV would drive the growth of the market. However, the market growth would be challenged by rigid competition, management challenges, lack of diagnostic facilities and high cost of medical care and legal regulations. A few notable trends may include growth in pharmaceutical research and development, collaboration, innovation and research, high demand for biomarker based tests, HBV treatments in development and government initiatives and public awareness.

The HBV market is fragmented in nature and the degree of fragmentation would accelerate during the forecast period. To make the most of the opportunities, market players are focusing more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Key players are investing significant amount of funds on the pharmaceutical research and development in order to expand the product portfolio of hepatitis B therapeutics, which is likely to help in the considerable growth of the global hepatitis b virus (HBV) market.

The fastest regional market is the U.S., due the presence of the well established healthcare infrastructure. With the increase in the prevalence of hepatitis B, the demand for treatment of the disease is becoming prominent. Therefore, some of the government and non-government organizations are taking the initiative to bring awareness about hepatitis B, which would help in the growth of the global HBV market in coming years.

Scope of the report:

The report provides a comprehensive analysis of the global Hepatitis B Virus (HBV) Market.

The major regional markets (the U.S., European Union and Japan) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Merck & Co., Bristol-Myers Squibb, Gilead Sciences, Arrowhead Pharmaceuticals and Arbutus Pharma are also presented in detail.

Key Target Audience:

Hepatitis B Virus Therapeutics Manufacturers

Pharmaceuticals and Biopharmaceutical Firms

End Users (Hospitals and Research Institutes)

Investment Banks

Healthcare and Medical Consultants

Government Bodies & Regulating Authorities


1. Market Overview
1.1 HBV: Introduction
1.2 Causes of Hepatitis B
1.3 Symptoms of Hepatitis B
1.4 Test and Diagnosis of Hepatitis B
1.5 Risk of Hepatitis B
1.6 HBV Blood Tests
Table 1: HBV Blood Tests and Indications
1.7 Chronic HBV Disease Phases
Table 2: Chronic HBV Disease Phases
1.8 Current HBV Treatments
Table 3: CHB Treatment Timeline
2. Impact of COVID-19
2.1 Growth in Government Spending on Healthcare
Table 4: Global Government Share on Health Spending (2019-2024)
2.2 COVID-19 Antiviral Drugs Candidates
2.3 Chloroquine and COVID-19
3. Global HBV Market Analysis
3.1 Global HBV Market
Table 5: Global HBV Market Forecast by Value (2021-2030)
3.2 Global HBV Market by Antiviral Drug Class
3.2.1 Global RNA Interference Antiviral Market Forecast by Value
Table 6: Global RNA Interference Antiviral Market Forecast by Value (2021-2030)
3.2.2 Global Entry Inhibitor Antiviral Market Forecast by Value
Table 7: Global Entry Inhibitor Antiviral Market Forecast by Value (2021-2030)
3.2.3 Global Core Inhibitor Antiviral Market Forecast by Value
Table 8: Global Core Inhibitor Antiviral Market Forecast by Value (2021-2030)
3.2.4 Global Antisense Antiviral Market Forecast by Value
Table 9: Global Antisense Antiviral Market Forecast by Value (2021-2030)
3.2.5 Global HBsAg Inhibitors Antiviral Market Forecast by Value
Table 10: Global HBsAg Inhibitors Antiviral Market Forecast by Value (2021-2030)
4. Regional Market Analysis
4.1 The US
4.1.1 The US HBV Market Forecast by Value
Table 11: The U.S. HBV Market Forecast by Value (2021-2030)
4.1.2 The US Chronic HBV Patients Forecast by Volume
Table 12: The U.S. Chronic HBV Patients by Volume (2021-2030)
4.1.3 The US Diagnosed HBV Patients Forecast by Volume
Table 13: The U.S. Diagnosed HBV Patients Forecast by Volume (2021-2030)
4.1.4 The US Treated HBV Patients Forecast by Volume
Table 14: The U.S. Treated HBV Patients Forecast by Volume (2021-2030)
4.2 European Union
4.2.1 European Union HBV Market Forecast by Value
Table 15: European Union HBV Market Forecast by Value (2021-2030)
4.2.2 European Union Chronic HBV Patients Forecast by Volume
Table 16: European Union Chronic HBV Patients Forecast by Volume (2021-2030)
4.2.3 European Union Diagnosed HBV Patients Forecast by Volume
Table 17: European Union Diagnosed HBV Patients Forecast by Volume (2021-2030)
4.2.4 European Union Treated HBV Patients Forecast by Volume
Table 18: European Union Treated HBV Patients Forecast by Volume (2021-2030)
4.3 Japan
4.3.1 Japan HBV Market Forecast by Value
Table 19: Japan HBV Market Forecast by Value (2021-2030)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Expansion of Pharmaceutical Industry
Table 20: Global Total Prescription Drug Sales (2020-2024)
5.1.2 Increase in Ageing Population
Table 21: Global Ageing Population – Above 60+ (2021-2030)
5.1.3 Increasing Healthcare Expenditure
Table 22: Global Healthcare Expenditure Per Capita (2017-2050)
5.1.4 Urbanization leading to Better Monitoring and Screening Procedures
Table 23: Global Urban Population (2010-2030)
5.1.5 Increase in Liver Cancer and Cirrhosis Deaths due to HBV
5.2 Market Trends
5.2.1 Growth in Pharmaceutical Research and Development
Table 24: Global Pharmaceutical Research and Development Expenditures (2021-2030)
5.2.2 Collaboration, Innovation and Research
5.2.3 High Demand for Biomarker Based Tests
5.2.4 HBV Treatments in Development
5.2.5 Government Initiatives and Public Awareness
5.3 Challenges
5.3.1 Rigid Competition
5.3.2 Management Challenges
5.3.3 Lack of Diagnostic Facilities and High cost of Medical Care
5.3.4 Legal Regulations
6. Competitive Landscape
6.1 Key Players – Revenue Comparison
Table 25: Key Players – Revenue Comparison (2019/2020)
6.2 Key Players – R&D Expenditure Comparison
Table 26: Key Players – R&D Expenditure Comparison (2019/2020)
6.3 Key Players – Market Capitalization Comparison
Table 27: Key Players – Market Capitalization Comparison (2021)
6.4 Global HBV Therapies in Development by Company
Table 28: Global HBV Therapies in Development by Company
6.5 Global Capsid Inhibitor Therapy in Development by Company
Table 29: Global Capsid Inhibitor Therapy in Development by Company
6.6 Global RNAi Gene Silencer Therapy in Development by Company
Table 30: Global RNAi Gene Silencer Therapy in Development by Company
7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Business Overview
7.1.2 Financial Overview
Table 31: Johnson & Johnson Total Sales and Net Earnings (2015-2019)
Table 32: Johnson & Johnson Total Sales by Segments (2019)
Table 33: Johnson & Johnson Total Sales by Regions (2019)
7.1.3 Business Strategies
7.2 Merck and Co.
7.2.1 Business Overview
7.2.2 Financial Overview
Table 34: Merck and Co. Sales and Net Income (2015-2019)
Table 35: Merck and Co. Sales by Segments (2019)
Table 36: Merck and Co. Sales by Regions (2019)
7.2.3 Business Strategies
7.3 Bristol-Myers Squibb
7.3.1 Business Overview
7.3.2 Financial Overview
Table 37: Bristol-Myers Squibb Total Revenue and Net Earnings (2015-2019)
Table 38: Bristol-Myers Squibb Total Revenue by Operations (2019)
Table 39: Bristol-Myers Squibb Total Revenue by Regions (2019)
7.3.3 Business Strategies
7.4 Gilead Sciences
7.4.1 Business Overview
7.4.2 Financial Overview
Table 40: Gilead Sciences Total Revenue and Net Income (2015-2019)
Table 41: Gilead Sciences Total Revenue by Operations (2019)
Table 42: Gilead Sciences Total Revenue by Regions (2019)
7.4.3 Business Strategies
7.5 Arrowhead Pharmaceuticals
7.5.1 Business Overview
7.5.2 Financial Overview
Table 43: Arrowhead Pharmaceuticals Revenue and Net Loss (Income) (2016-2020)
7.5.3 Business Strategies
7.6 Arbutus Pharma
7.6.1 Business Overview
7.6.2 Financial Overview
Table 44: Arbutus Revenue and Net Loss (2015-2019)
7.6.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook